<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Milestone Pharmaceuticals Inc. — News on 6ix</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc</link>
<description>Latest news and press releases for Milestone Pharmaceuticals Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/milestone-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683599cb78dffbe2df10604c.webp</url>
<title>Milestone Pharmaceuticals Inc.</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc</link>
</image>
<item>
<title>Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-reset-psvt-registry-to-generate-real-world-evidence-on-cardamysttm-etripamil-nasal-spray-in-patients-with-psvt</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-reset-psvt-registry-to-generate-real-world-evidence-on-cardamysttm-etripamil-nasal-spray-in-patients-with-psvt</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium MONTREAL and CHARLOTTE, N.C., April</description>
</item>
<item>
<title>Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 12:30:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026. A webcast of the presentation will be available on April 13th at 3:45 PM EDT. The webcast will be available to watch here and there wi</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-that-cardamysttm-etripamil-nasal-spray-is-available-on-express-scripts-commercial-national-formularies</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-that-cardamysttm-etripamil-nasal-spray-is-available-on-express-scripts-commercial-national-formularies</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-update-on-the-commercial-launch-of-cardamysttm-etripamil-nasal-spray-for-the-treatment-of-psvt</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-update-on-the-commercial-launch-of-cardamysttm-etripamil-nasal-spray-for-the-treatment-of-psvt</guid>
<pubDate>Fri, 20 Mar 2026 11:12:00 GMT</pubDate>
<description>FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $10</description>
</item>
<item>
<title>Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-present-data-on-cardamysttm-etripamil-nasal-spray-at-the-2026-american-college-of-cardiology-annual-scientific-session</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-present-data-on-cardamysttm-etripamil-nasal-spray-at-the-2026-american-college-of-cardiology-annual-scientific-session</guid>
<pubDate>Mon, 16 Mar 2026 12:13:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled “Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia (PSVT)” will be featured at the 2026 American College of Cardiology Annual Scientific Session (ACC.2</description>
</item>
<item>
<title>Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-20-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-20-2026-3</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ETMONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792Internati</description>
</item>
<item>
<title>Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestoner-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestoner-pharmaceuticals-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston. A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days fo</description>
</item>
<item>
<title>Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-appoints-david-sandoval-130000534</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-appoints-david-sandoval-130000534</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal sprayMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute sympt</description>
</item>
<item>
<title>Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-inducement-grants-130000557</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-inducement-grants-130000557</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 419,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new empl</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-u-availability-130000913</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-u-availability-130000913</guid>
<pubDate>Mon, 26 Jan 2026 13:00:00 GMT</pubDate>
<description>CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured patientsLaunch supported by comprehensive patient assistance program offering benefits verification and reimbursement support MONTREAL and CHARLOTTE, N.C., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that CARDAMYST™ (etripamil) nasal spray, its fir</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-acceptance-marketing-130000118</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-acceptance-marketing-130000118</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the acceptance of a Marketing Authoriza</description>
</item>
<item>
<title>Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-receives-fda-approval-cardamyst-010000986</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-receives-fda-approval-cardamyst-010000986</guid>
<pubDate>Sat, 13 Dec 2025 01:00:00 GMT</pubDate>
<description>First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc</description>
</item>
<item>
<title>Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-third-quarter-120100660</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-third-quarter-120100660</guid>
<pubDate>Wed, 12 Nov 2025 12:01:00 GMT</pubDate>
<description>PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA Approval $82.6 million in Cash at September 30; Successful Equity Offering and Amended Royalty Purchase Agreement Provide Resources for Successful Launch MONTREAL and CHARLOTTE, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results</description>
</item>
<item>
<title>Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-analysis-investigational-130000610</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-analysis-investigational-130000610</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>Data show consistent efficacy, safety, and tolerability findings across multiple clinical trials that evaluated self-administered etripamilMONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that new data analyses surrounding its lead investigational product for the management of paroxysmal supraventricula</description>
</item>
<item>
<title>Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-data-etripamil-120000796</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-data-etripamil-120000796</guid>
<pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil</description>
</item>
<item>
<title>Milestone® Pharmaceuticals to Present at Upcoming Conferences</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-upcoming-conferences-120000757</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-present-upcoming-conferences-120000757</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8 – 10, 2025, in New York. A webcast of the H.C. Wainwright presentation will be availa</description>
</item>
<item>
<title>Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-second-quarter-110500426</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-reports-second-quarter-110500426</guid>
<pubDate>Tue, 12 Aug 2025 11:05:00 GMT</pubDate>
<description>FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Total Gross Proceeds of up to $170 Million if all Warrants are Exercised $75 Million Royalty Purchase Agreement Payment from RTW Extended Through End of 2025 MONTREAL and CHARLOTTE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-pricing-52-133000376</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-pricing-52-133000376</guid>
<pubDate>Fri, 11 Jul 2025 13:30:00 GMT</pubDate>
<description>MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 3</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces Proposed Public Offering</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-proposed-public-100100696</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-proposed-public-100100696</guid>
<pubDate>Fri, 11 Jul 2025 10:01:00 GMT</pubDate>
<description>MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants</description>
</item>
<item>
<title>Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray</title>
<link>https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-fda-acceptance-100000288</link>
<guid isPermaLink="true">https://6ix.com/company/milestone-pharmaceuticals-inc/news/milestone-pharmaceuticals-announces-fda-acceptance-100000288</guid>
<pubDate>Fri, 11 Jul 2025 10:00:00 GMT</pubDate>
<description>New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment</description>
</item>
</channel>
</rss>